<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469937</url>
  </required_header>
  <id_info>
    <org_study_id>VICC RAD 0521</org_study_id>
    <secondary_id>VU-VICC-RAD-0521</secondary_id>
    <secondary_id>VU-IRB-051043</secondary_id>
    <nct_id>NCT00469937</nct_id>
  </id_info>
  <brief_title>Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases</brief_title>
  <official_title>A Phase I Study of Lithium During Whole Brain Radiotherapy for Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as&#xD;
      lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium&#xD;
      together with radiation therapy may allow a higher dose of radiation therapy to be given so&#xD;
      that more tumor cells are killed.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lithium when given&#xD;
      together with whole-brain radiation therapy in treating patients with brain metastases from&#xD;
      primary cancer outside the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of concurrent lithium carbonate and whole-brain radiotherapy,&#xD;
           as measured by safety and compliance, in patients with primary extracranial malignancy&#xD;
           and brain metastases.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of lithium carbonate.&#xD;
&#xD;
      Patients receive oral lithium carbonate twice daily on days 1-7 and 2-4 times daily on days&#xD;
      8-21. Patients undergo whole-brain radiotherapy once daily on days 8-12 and 15-19.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of lithium carbonate until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Quality of life and mental status are assessed at baseline, on days 1, 8, and 15, at 1-month&#xD;
      post-treatment, and then periodically thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 month and then periodically&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of concurrent lithium carbonate and whole-brain radiotherapy as measured by safety and compliance</measure>
    <time_frame>Safety is measured by the rate of grade 3 or worse</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Cognitive/Functional Effects</condition>
  <condition>Neurotoxicity</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium carbonate</intervention_name>
    <description>Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>lithium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
    <description>cognitive assessment</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>quality-of-life assessment</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed extracranial primary malignancy&#xD;
&#xD;
               -  Multiple (i.e., &gt; 3) brain metastases OR &lt; 3 metastases with at least 1&#xD;
                  metastasis &gt; 4.0 cm in diameter&#xD;
&#xD;
               -  Not eligible for radiosurgery&#xD;
&#xD;
          -  No requirement for immediate whole-brain radiotherapy&#xD;
&#xD;
          -  No metastases to the midbrain or brainstem&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  ANC &gt; 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  BUN &lt; 25 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  ALT ≤ 2 times normal&#xD;
&#xD;
          -  Sodium &gt; 136 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neurologically stable&#xD;
&#xD;
               -  No seizure disorders or seizures due to brain metastases&#xD;
&#xD;
          -  No medical illnesses or psychiatric conditions that would preclude completion of study&#xD;
             treatment&#xD;
&#xD;
          -  No sensory neuropathy ≥ grade 2&#xD;
&#xD;
          -  No bipolar disorder&#xD;
&#xD;
          -  No thyroid disease&#xD;
&#xD;
          -  No QTc interval prolongation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent NSAIDs, angiotensin-converting enzyme&#xD;
             inhibitors (e.g., enalapril or captopril), calcium channel blockers, diuretics,&#xD;
             selective cyclooxygenase-2 inhibitors, acetazolamide, urea, xanthine, or alkalinizing&#xD;
             agents (e.g., sodium bicarbonate)&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck area&#xD;
&#xD;
          -  No prior radiosurgery&#xD;
&#xD;
          -  No concurrent radiotherapy to other sites&#xD;
&#xD;
          -  No concurrent anticonvulsants due to brain metastases&#xD;
&#xD;
          -  No concurrent psychoactive drugs&#xD;
&#xD;
          -  No concurrent thyroid medications&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Lu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>February 26, 2012</last_update_submitted>
  <last_update_submitted_qc>February 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>David Gius, MD, PhD</investigator_full_name>
    <investigator_title>Professor; Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>neurotoxicity</keyword>
  <keyword>cognitive/functional effects</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>adult tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

